
What is claimed is:

1. A compound according to Formula (III-m)



Formula (III-m)

or an optically pure stereoisomer, pharmaceutically acceptable salt or solvate, wherein

R_2 is independently selected from hydrogen, deuterium, unsubstituted or substituted alkyl, unsubstituted or substituted allyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl,


R_6 and R_7 are selected from hydrogen, deuterium, and halogen,


R_8 is an unsubstituted or partially or fully deuterated methyl or ethyl, and


R_9 is a partially or fully deuterated ethyl.

.


2. The compound of claim 1, wherein R_2 is independently selected from hydrogen, deuterium, and an unsubstituted or partially or fully deuterated methyl or ethyl.
3. The compound of claim 1, wherein R_8 and R_9 are not both unsubstituted or partially or fully deuterated ethyl.
4. A compound, wherein the compound is:








or




, or a pharmaceutically acceptable salt thereof.

5. A compound




, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 4, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 4, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 4, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

9. Use of a therapeutically effective amount of a compound of any one of claims 1 to 8 in the manufacture of a medicament for the treatment of major depressive disorder (MDD), treatment-resistant depression (TRD), or combinations thereof.

10. Use of a therapeutically effective amount of a compound of any one of claims 1 to 8 in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disorder (COPD).

11. Use of a therapeutically effective amount of a compound of any one of claims 1 to 8 in the manufacture of a medicament for the treatment of atherosclerosis.

12. Use of a therapeutically effective amount of a compound of any one of claims 1 to 8 in the manufacture of a medicament for the treatment of alcohol use disorder.